Squarepoint’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Squarepoint’s Portfolio CRXT Stock Details CRXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-29,085	Closed	-$11K	–	3641
2022 Q2	$11K	Buy	+29,085	New	+$20.4K	﹤0.01%	2788

Other funds holding CRXT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Squarepoint's CRXT Position: Q3 2022 in Review

Squarepoint sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 29,085 shares — an estimated $11K sold.

Squarepoint first reported a position in CRXT in Q2 2022 and held it in 1 quarter. The position peaked at $11K in Q2 2022. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

Squarepoint reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Squarepoint sold 29,085 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $11K.
Squarepoint first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
Squarepoint's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $11K in Q2 2022.
2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Squarepoint's 13F filing for Q3 2022, filed 14 Nov 2022.